• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian journal of palliative care >Bleomycin in Hodgkin's lymphoma – A boon or a bane? – A retrospective study of bleomycin pulmonary toxicity in Hodgkin's lymphoma
【24h】

Bleomycin in Hodgkin's lymphoma – A boon or a bane? – A retrospective study of bleomycin pulmonary toxicity in Hodgkin's lymphoma

机译：霍奇金淋巴瘤中的博来霉素–恩还是祸？ –博来霉素对霍奇金淋巴瘤的肺毒性的回顾性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Hodgkin's lymphoma (HL) is one of the most curable malignancies with cure rates of above 85% across all stages. Bleomycin containing regimen is routinely employed in the treatment of HL. Pulmonary toxicity due to this drug is the most feared side effect in these regimens where the mortality rate is approximately 2%–3%. We have conducted this study to assess the genetic susceptibility among the Indian HL patients to bleomycin pulmonary toxicity (BPT). Materials and Methods: In a retrospective study conducted at a tertiary care hospital from South India between January 2013 and May 2019, we reviewed 100 HL patients who were treated with bleomycin-containing regimen (adriamycin, bleomycin, vinblastine, and dacarbazine or cyclophosphamide, vincristine, procarbazine, and prednisone/adriamycin, bleomycin, and vinblastine) for BPT. Results: A total of 100 patients with HL who had received bleomycin-containing regimen were analyzed, which included 23 females and 77 males. Twenty-nine patients had BPT and five deaths were attributed to the same. Radiology reports showed that 15 patients had acute BPT and eight patients had chronic changes. Four patients had rare findings of bleomycin-induced lung damage and computed tomography of the chest could not be done for two patients, whose chest X-ray showed features suggestive of BPT. Conclusion: The incidence of bleomycin induced pulmonary toxicity and mortality was significantly higher in our study compared to that of other Western studies. This could be probably due to the increased susceptibility of the Indian patients to bleomycin induced lung damage. In a highly curable cancer such as HL, it is unacceptable to have such a high life-threating toxicity. Hence, an alternative chemotherapy regimen without bleomycin is to be explored which would prevent toxicity and hence the compromise on survival.
机译：简介：霍奇金淋巴瘤（HL）是最可治愈的恶性肿瘤之一，所有阶段的治愈率均在85％以上。含有博来霉素的方案通常用于治疗HL。在死亡率约为2％–3％的这些方案中，这种药物引起的肺毒性是最令人担忧的副作用。我们进行了这项研究，以评估印度HL患者对博来霉素肺毒性（BPT）的遗传易感性。材料和方法：在2013年1月至2019年5月之间于南印度一家三级医院进行的一项回顾性研究中，我们回顾了100例接受含博来霉素方案（阿霉素，博来霉素，长春碱和达卡巴嗪或环磷酰胺，长春新碱）治疗的HL患者，丙卡巴嗪和泼尼松/阿霉素，博来霉素和长春碱）。结果：共分析了100例接受博来霉素治疗的HL患者，其中23例女性和77例男性。 29名患者患有BPT，其中5例死亡归因于同一例。放射学报告显示15例患者患有急性BPT，8例患者患有慢性改变。四名患者很少发现博来霉素诱导的肺损伤，并且两名患者无法进行胸部计算机断层扫描，其两名患者的胸部X光片显示出提示BPT的特征。结论：博莱霉素诱导的肺毒性和死亡率的发生率比其他西方研究高得多。这可能是由于印度患者对博来霉素诱导的肺损伤的敏感性增加。在高度可治愈的癌症如HL中，具有如此高的威胁生命的毒性是不可接受的。因此，将探索不使用博来霉素的替代化学疗法，以防止毒性并因此损害生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号